308 related articles for article (PubMed ID: 26924542)
21. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.
Mizutani T; Shinoda M; Tanaka Y; Kuno T; Hattori A; Usui T; Kuno N; Osaka T
Drug Metab Rev; 2005; 37(1):235-52. PubMed ID: 15747502
[TBL] [Abstract][Full Text] [Related]
22. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
Klein R; Zanger UM; Berg T; Hopf U; Berg PA
Clin Exp Immunol; 1999 Nov; 118(2):290-7. PubMed ID: 10540193
[TBL] [Abstract][Full Text] [Related]
23. Animal models for autoimmune hepatitis.
Christen U; Holdener M; Hintermann E
Autoimmun Rev; 2007 Apr; 6(5):306-11. PubMed ID: 17412303
[TBL] [Abstract][Full Text] [Related]
24. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
25. New animal models for autoimmune hepatitis.
Christen U; Hintermann E; Jaeckel E
Semin Liver Dis; 2009 Aug; 29(3):262-72. PubMed ID: 19675999
[TBL] [Abstract][Full Text] [Related]
26. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice.
Hintermann E; Ehser J; Christen U
J Vis Exp; 2012 Feb; (60):. PubMed ID: 22331063
[TBL] [Abstract][Full Text] [Related]
27. Aetiopathogenesis of autoimmune hepatitis.
Longhi MS; Ma Y; Mieli-Vergani G; Vergani D
J Autoimmun; 2010 Feb; 34(1):7-14. PubMed ID: 19766456
[TBL] [Abstract][Full Text] [Related]
28. S100A8 Production in CXCR2-Expressing CD11b+Gr-1high Cells Aggravates Hepatitis in Mice Fed a High-Fat and High-Cholesterol Diet.
Mukai K; Miyagi T; Nishio K; Yokoyama Y; Yoshioka T; Saito Y; Tanaka S; Shigekawa M; Nawa T; Hikita H; Sakamori R; Yoshihara H; Imai Y; Hiramatsu N; Tatsumi T; Takehara T
J Immunol; 2016 Jan; 196(1):395-406. PubMed ID: 26608915
[TBL] [Abstract][Full Text] [Related]
29. Development of a New Murine Model of Type 2 Autoimmune Hepatitis Using a Human Liver Protein.
Thomas-Dupont P; Grube-Pagola P; Izaguirre-Hernández IY; Hernández-Flores KG; Sánchez-Marce EE; Cano-Contreras AD; Remes-Troche JM; Vivanco-Cid H
Am J Pathol; 2022 Jan; 192(1):21-30. PubMed ID: 34717895
[TBL] [Abstract][Full Text] [Related]
30. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction.
Cheng C; Tan J; Qian W; Zhang L; Hou X
Life Sci; 2018 Sep; 209():157-166. PubMed ID: 30096384
[TBL] [Abstract][Full Text] [Related]
31. Anti-CYP2D6 antibodies detected by quantitative radioligand assay and relation to antibodies to liver-specific arginase in patients with autoimmune hepatitis.
Kimura M; Tatsumi KI; Tada H; Izumi Y; Kaneko A; Kato M; Masuzawa M; Ikemoto M; Yabusaki Y; Hidaka Y; Amino N
Clin Chim Acta; 2002 Feb; 316(1-2):155-64. PubMed ID: 11750286
[TBL] [Abstract][Full Text] [Related]
32. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
33. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
34. L-lysine supplementation attenuates experimental autoimmune hepatitis in a chronic murine model.
Lei Y; Chen Y; Wang S; Lin Z; Han P; Tian D; Wang H; Liu M
Exp Anim; 2024 Feb; 73(1):83-92. PubMed ID: 37648521
[TBL] [Abstract][Full Text] [Related]
35. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
36. Chemical induced inflammation of the liver breaks tolerance and results in autoimmune hepatitis in Balb/c mice.
Chi G; Pei JH; Ma QY; Ru YX; Feng ZH
Immunol Lett; 2020 Feb; 218():44-50. PubMed ID: 31794800
[TBL] [Abstract][Full Text] [Related]
37. Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis.
Yoshimine Y; Uto H; Kumagai K; Mawatari S; Arima S; Ibusuki R; Mera K; Nosaki T; Kanmura S; Numata M; Tamai T; Moriuchi A; Tsubouchi H; Ido A
Oncol Rep; 2015 Apr; 33(4):1657-66. PubMed ID: 25607821
[TBL] [Abstract][Full Text] [Related]
38. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature.
Almanza D; Gharaee-Kermani M; Zhilin-Roth A; Rodriguez-Nieves JA; Colaneri C; Riley T; Macoska JA
Dig Dis Sci; 2019 May; 64(5):1257-1269. PubMed ID: 30519850
[TBL] [Abstract][Full Text] [Related]
40. CD4
Her Z; Tan JHL; Lim YS; Tan SY; Chan XY; Tan WWS; Liu M; Yong KSM; Lai F; Ceccarello E; Zheng Z; Fan Y; Chang KTE; Sun L; Chang SC; Chin CL; Lee GH; Dan YY; Chan YS; Lim SG; Chan JKY; Chandy KG; Chen Q
Front Immunol; 2020; 11():580968. PubMed ID: 33013934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
